Issue of Share Options/PDMR Shareholdings

Diaceutics PLC
19 May 2023
 

 19 May 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces the issue of 1,276,707 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

 

Share Options were granted as follows:

 

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Effective Grant date

Peter Keeling, CEO

102,468

435,313

0.52%

18 May 2023

Nick Roberts, CFO

67,034

158,872

0.19%

18 May 2023

Ryan Keeling, CIO

93,407

409,851

0.49%

18 May 2023

Julie Browne, COO and PDMR

67,109

169,047

0.20%

18 May 2023

Jordan Clark, CCO and PDMR

65,245

115,740

0.14%

18 May 2023

Susanne Munksted, CPO and PDMR

68,834

249,199

0.30%

18 May 2023

Other employees (43 persons)

812,610

1,675,537

1.98%

18 May 2023

 

 

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth in the proportion of subscription revenue and Total Shareholder Return ("TSR") during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 18 May 2023. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

 

Following this grant, the total number of share options outstanding in the Company is 3,826,487 representing approximately 4.52% of its current issued share capital of 84,461,386.

 

Enquiries:

Diaceutics PLC 


Peter Keeling, Chief Executive Officer

Via Alma PR 

Nick Roberts, Chief Financial Officer




Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison, Nick Harland, Nick Adams




Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde, Kieran Breheny, Matthew Young

diaceutics@almapr.co.uk


About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real‐world healthcare data insights, advisory services and innovative platform enabled solutions.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Peter Keeling

2

Reason for notification

  

a.

Position/Status

Chief Executive Officer, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

102,468



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Nick Roberts

2

Reason for notification

  

a.

Position/Status

Chief Finance Officer, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

67,034



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Ryan Keeling

2

Reason for notification

  

a.

Position/Status

Chief Innovation Officer, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

93,407



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Julie Browne

2

Reason for notification

  

a.

Position/Status

Chief Operations Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

67,109



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

  

a.

Position/Status

Chief Commercial Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

65,245



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

  

a.

Position/Status

Chief Precision Medicine Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)







Price(s)

Volume(s)


Exercise price of 0.2p per share

68,834



e.

Date of the transaction

18 May 2023

f.

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings